Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 1.00 |
| ▸ | KDR | P35968 | 15/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 14/20 | 1.00 |
| ▸ | FLT1 | P17948 | 14/20 | 1.00 |
| ▸ | FLT4 | P35916 | 14/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.84 |
| ▸ | TEK | Q02763 | 2/20 | 0.84 |
| ▸ | KIF5B | P33176 | 2/20 | 0.84 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.84 |
| ▸ | PLK4 | O00444 | 1/20 | 0.84 |
| ▸ | CIT | O14578 | 1/20 | 0.84 |
| ▸ | GAK | O14976 | 1/20 | 0.84 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.84 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.84 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.84 |
| ▸ | STK10 | O94804 | 1/20 | 0.84 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.84 |
| ▸ | ABL1 | P00519 | 1/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12534441 | 0.92 | EGFR (0.85) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL29352879 | 0.91 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL28224661 | 0.91 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL9044 | 0.91 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL19154592 | 0.91 | EGFR (0.84) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL4637084 | 0.90 | EGFR (0.98) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1614458 | 0.90 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL2137353 | 0.90 | EGFR (0.98) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL8173228 | 0.90 | EGFR (0.82) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL21473656 | 0.90 | EGFR (0.81) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2019-01-03 | — | — | US | claimed |
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | claimed |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2016-05-12 | — | — | US | claimed |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | claimed |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB | 2007-11-15 | — | — | US | claimed |
| US-7173038-B1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | claimed |
| EP-1676845-A1 | New quinazoline derivatives | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | claimed |
| EP-1244647-B1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-21 | — | — | EP | claimed |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210206791-A1 | SELECTIVE METAL-MEDIATED ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-07-08 | — | — | US | disclosed |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2020-08-20 | — | — | US | disclosed |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | GENZYME CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3092243-B1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | CENTRE NAT RECH SCIENT (FR) | 2019-06-19 | — | — | EP | disclosed |
| US-7173038-B1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| EP-1676845-A1 | New quinazoline derivatives | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1244647-B1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| EP-1658849-A2 | Therapeutic combinations of antihypertensive and antiangiogenic agents | AstraZeneca AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | EGFR 199/4885KDR 3/4885FGFR1 161/4885 |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | SRC, TEK, FLT4 | EGFR 124/4885KDR 5/4885FGFR1 50/4885 |
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 207/4885KDR 3/4885FGFR1 154/4885 |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | FLT1, FLT4, KDR | EGFR 183/4885KDR 3/4885FGFR1 143/4885 |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | EGFR 179/4885KDR 3/4885FGFR1 196/4885 |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | EGFR 475/4885KDR 5/4885FGFR1 1/4885 |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | EGFR 183/4885KDR 3/4885FGFR1 143/4885 |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | TEK, TIE1, FLT1 | EGFR 51/4885KDR 5/4885FGFR1 9/4885 |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 181/4885KDR 3/4885FGFR1 135/4885 |
| US-20210206791-A1 | SELECTIVE METAL-MEDIATED ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES | SCLY, SELENOI, PTMS | EGFR 486/4885KDR 4219/4885FGFR1 4071/4885 |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 181/4885KDR 3/4885FGFR1 135/4885 |
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 179/4885KDR 3/4885FGFR1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.